The involvement of vimentin in copper-induced regression of cardiomyocyte hypertrophy
- PMID: 26168186
- DOI: 10.1039/c5mt00094g
The involvement of vimentin in copper-induced regression of cardiomyocyte hypertrophy
Abstract
Dietary copper supplementation reverses the pressure overload-induced cardiac hypertrophy. Activation of vascular endothelial growth factor receptor-1 (VEGFR-1) and cyclic guanosine monophosphate (cGMP)-dependent protein kinase-1 (PKG-1) is required for the regression. The present study was undertaken to determine the link between VEGFR-1 and PKG-1 in copper regression of cardiomyocyte hypertrophy. Human cardiac myocytes (HCM) or primary cultures of neonatal rat cardiomyocytes were exposed to phenylephrine (PE) at a final concentration of 100 μM for 48 h to induce cell hypertrophy. Copper sulfite was added to cultures of hypertrophic cardiomyocytes at a final concentration of 5 μM elemental copper and incubated for 24 h to reverse cell hypertrophy. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis identified a 56 kDa copper-binding protein, vimentin, which was co-immunoprecipitated with VEGFR-1 and PKG-1. Copper supplementation increased vimentin levels and enhanced PKG-1 activity. Gene silencing using siRNA targeting vimentin prevented copper-induced elevation of vimentin, depressed the activity of PKG-1, and blocked the copper-induced regression of cardiomyocyte hypertrophy. This study demonstrates that vimentin is critically involved in the VEGFR-1 mediated activation of the PKG-1 signaling pathway, leading to regression of cardiomyocyte hypertrophy.
Similar articles
-
Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway.Cardiovasc Res. 2009 Oct 1;84(1):54-63. doi: 10.1093/cvr/cvp178. Epub 2009 Jun 19. Cardiovasc Res. 2009. PMID: 19542178 Free PMC article.
-
Cytochrome c oxidase is essential for copper-induced regression of cardiomyocyte hypertrophy.Cardiovasc Toxicol. 2010 Sep;10(3):208-15. doi: 10.1007/s12012-010-9080-0. Cardiovasc Toxicol. 2010. PMID: 20582486
-
Role of copper in regression of cardiac hypertrophy.Pharmacol Ther. 2015 Apr;148:66-84. doi: 10.1016/j.pharmthera.2014.11.014. Epub 2014 Dec 1. Pharmacol Ther. 2015. PMID: 25476109 Review.
-
Copper reverses cardiomyocyte hypertrophy through vascular endothelial growth factor-mediated reduction in the cell size.J Mol Cell Cardiol. 2008 Jul;45(1):106-17. doi: 10.1016/j.yjmcc.2008.03.022. Epub 2008 Apr 9. J Mol Cell Cardiol. 2008. PMID: 18495151 Free PMC article.
-
Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets.Pharmacol Ther. 2012 Sep;135(3):337-54. doi: 10.1016/j.pharmthera.2012.06.006. Epub 2012 Jun 29. Pharmacol Ther. 2012. PMID: 22750195 Free PMC article. Review.
Cited by
-
Phosphoproteomic Analysis Reveals Downstream PKA Effectors of AKAP Cypher/ZASP in the Pathogenesis of Dilated Cardiomyopathy.Front Cardiovasc Med. 2021 Dec 13;8:753072. doi: 10.3389/fcvm.2021.753072. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34966794 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
